GENE ONLINE|News &
Opinion
Blog

2021-05-04| Trials & Approvals

Full Approval of Treatment Standard Forces Avrobio to Adjust Fabry Disease Therapy Plans

by Daniel Ojeda
Share To

On May 3rd, Massachusetts-based Avrobio announced updated regulatory plans for AVR-RD-01, its investigational gene therapy candidate. The change is an outcome of the full approval received by Sanofi’s Fabrazyme, the current standard therapy for treating Fabry disease. To be in sync with the FDA’s updated requirements, Avrobio has now proposed a head-to-head clinical trial to evaluate AVR-RD-01 against Fabrazyme.

Fabry disease is a rare disease caused by mutations in the GLA gene that leads to defects in fat metabolism. Victims typically suffer from chronic pain, gastrointestinal complications, hearing loss, kidney issues, and an increased risk of stroke and heart attacks.

In 2003, Fabrazyme became the first enzyme replacement therapy to receive accelerated approval for the condition. After nearly two decades, it received the FDA’s full approval last month. This development has changed the regulatory paths available for new investigational therapies. Therefore, companies are now pivoting to meet the new requirements.

AVR-RD-01

Avrobio has been testing AVR-RD-01, its ex vivo lentiviral-based gene therapy for treating Fabry disease, since 2017. Their therapy works by modifying the hematopoietic stem cells of patients to introduce a functional GLA gene. To support the use of AVR-RD-01 in a broad population, Avrobio was planning to update their ongoing Phase 2 clinical trial by including women, eliminating antibody exclusion, and collecting data on additional parameters that could influence the effectiveness of the therapy. They also planned a second confirmatory clinical trial.

To comply with the new FDA requirements, they will modify their plans to compare AVR-RD-01 to Fabrazyme directly and include clearance of GL-3 on biopsied renal tissue as a primary endpoint. The scope, size, and duration will be maintained. After the announcement, Avrobio stock sank almost 19% and closed shy of $9.5.

Avrobio will be consulting with the FDA for the approval of its plan, and they hope to start registration in mid-2022. The full approval of Fabrazyme could also have consequences in the requirements of other regulatory bodies abroad. For this reason, Avrobio plans to discuss its upcoming trial with the European Medicines Agency.

“We believe we have a potential new path to pursue full approval for investigational AVR-RD-01 as a first-line therapy for Fabry disease by conducting a single, head-to-head registration trial versus Fabrazyme using a kidney biopsy surrogate endpoint similar to our FAB-GT Phase 2 trial, where we have seen 100% and 87% substrate reductions at one-year post-gene therapy in the two patients with evaluable kidney biopsies,” said Geoff MacKay, CEO, and President of AVROBIO. “We plan to design a registration trial with a scope, size, and duration comparable to other gene therapy trials.”

Other Candidates

The full approval of Fabrazyme will also affect other experimental gene replacement therapies in the fray, namely Protalix Therapeutics’ PRX-102, Freeline Therapeutics’ FLT190, and Sangamo Therapeutics’ ST-920. It will be interesting to see how these companies would adjust clinical trials of their candidates.

Editor: Rajaneesh K. Gopinath, Ph.D.

Related Article: FDA Rejects Protalix’s Enzyme Replacement Therapy for Rare Genetic Disease

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Orchard Therapeutics’ Gene Therapy for Rare Neurological Disorder Wins FDA Approval
2024-03-20
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top